Phase I Dose Escalation Trial of the Novel Proteasome Inhibitor Carfilzomib in Patients with Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

The proteasome complex degrades proteins involved in a variety of cellular processes and is a powerful therapeutic target in several malignancies. Carfilzomib is a potent proteasome inhibitor which induces rapid CLL cell apoptosis in vitro. We conducted a phase I dose-escalation trial to determine s...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Leuk Lymphoma
Hoofdauteurs: Awan, Farrukh T., Flynn, Joseph M., Jones, Jeffrey A., Andritsos, Leslie A., Maddocks, Kami J., Sass, Ellen J., Lucas, Margaret S., Chase, Weihong, Waymer, Sharon, Ling, Yonghua, Jiang, Yao, Phelps, Mitch A., Byrd, John C., Lucas, David M., Woyach, Jennifer A.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2015
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4835239/
https://ncbi.nlm.nih.gov/pubmed/25669927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2015.1014368
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items